摘要
目的观察乳腺癌患者中COX-2的表达及其与HER-2/neu表达的关系,分析COX-2表达对乳腺癌患者DFS的影响。方法应用免疫组化方法检测179例原发性乳腺癌患者标本的COX-2表达及HER-2/neu表达。结果共有25例(13.9%)标本中COX-2呈过表达,并且与HER-2/ neu表达(61/179,34.1%)显著相关(P=0.013)。在单因素生存分析中,COX-2过表达与无疾病生存期显著相关(P=0.029),而COX-2与HER-2/neu共表达患者也有无疾病生存期缩短的趋势。但是多因素分析提示,COX-2过表达与无疾病生存期无显著关系(RR 0.907,95%CI 0.309～2.65,P= 0.858)。结论在人类乳腺癌中,COX-2与HER-2/neu存在共表达。而COX-2与HER-2/neu共表达提示预后差。因此,COX-2选择性抑制剂的临床应用可能是乳腺癌患者治疗的一种新策略。
Objective To observe the expression of COX-2 and its relation to HER-2/neu expression in patients with breast cancer, and to analyze the impact of COX-2 expression on disease-free survival in breast cancer patients. Methods The expression of COX-2 and HER-2/neu was determined by immunohistochemistry in 179 patients with primary breast cancer. Results Expression of COX-2 was detected in 13. 9% of breast carcinoma samples and was significantly associated with HER-2/neu expression （P = 0. 013）. In univariate survival analysis ,a significant association was observed between expression of COX-2 and disease-free survival（P =0. 029）. However, in the multivariate analysis, expression of COX-2 had no significant relation to disease-free survival （ RR 0. 907,95% CI 0. 309-2. 65, P = 0. 858 ）. Conclusion There is co-expression of COX-2 and HER-2/neu in breast carcinoma. Co-expression of COX-2 and HER-2/ neu may be a negative survival factor for disease free survival, therefore treatment with selective inhibitors of COX-2 may be an additional option for treatment of patients with breast carcinoma.
出处
《中国肿瘤临床与康复》
2008年第6期484-488,共5页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
国家自然科学基金资助(30672424)
